Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Sun Pharmaceutical Industries Limited ( (IN:SUNPHARMA) ) has provided an update.
Sun Pharmaceutical Industries Limited announced that the US FDA has classified their Baska facility inspection status as Official Action Indicated (OAI) following an inspection conducted in September 2025. Despite the OAI classification, the company continues to manufacture and supply approved products to the US market and is actively working with the FDA to bring the facility into full compliance, which highlights their commitment to meeting regulatory standards and ensuring uninterrupted supply to stakeholders.
More about Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited is a leading global pharmaceutical company based in India, specializing in the development, manufacturing, and marketing of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company primarily focuses on providing high-quality, affordable medicines and has a significant presence in the US market.
Average Trading Volume: 83,314
Technical Sentiment Signal: Strong Buy
Current Market Cap: 4277.4B INR
For detailed information about SUNPHARMA stock, go to TipRanks’ Stock Analysis page.